CD4 and relapsing-remitting multiple sclerosis: In the present study, we focus on the effect of natalizumab treatment on miR-17 expression ex vivo by comparing miR-17 expressions in CD4+ T cells from natalizumab treated versus untreated RRMS patients and in in vitro natalizumab-induced experiments.